Diabetes
Study Identifies OCT-A Parameters to Predict DME Treatment Response
At baseline, patients who experienced good outcomes on ranibizumab therapy tended to have higher vascular densities in the superficial and deep capillary plexuses and smaller FAZ areas.
10/04/2024
Ultra-Widefield FA Imaging Best for Assessing DR Progression Risk
A post hoc analysis found that peripheral lesions beyond conventional ETDRS fields were significantly associated with an increased risk of disease worsening.
09/20/2024
OCT-A Can Detect Early Changes in Kidney Function
Fundus blood flow parameters may aid detection and monitoring of diabetic complications.
09/19/2024
Key Social Determinants Contribute to Inequities in Diabetic Eye Care Access
Study finds rural location, insurance type and preexisting conditions all foster disparities among high-risk groups.
09/17/2024
Study Links Diabetes Subtypes to Accelerated Retinal Thinning
After following patients for four years, researchers identified distinct rates of choroidal and ganglion cell layer loss and are advocating for adjusted screening intervals in these populations.
09/10/2024
Sequence Matters in Combined Treatment Approach for PDR, Study Shows
Patients who received PRP before anti-VEGF were more likely to undergo pars plana vitrectomy for vitreous hemorrhage or RD than those treated in the reverse order.
09/04/2024
Researchers Use Algorithm to Create New Severity Scale for Diabetic Macular Ischemia
It’s based on the distribution of capillary nonperfusion on OCT-A.
08/29/2024
GLP-1 Agonists May Protect Against Glaucoma in Type 2 Diabetes Patients
Compared to metformin, these agents conferred a significantly lower incidence of POAG, ocular hypertension and need for first-line treatments.
08/27/2024
Features of Capillaries Improve Classification Performance of DR
Using OCT angiography, researchers extracted characteristics specific to large vessels that yielded better accuracy of categorizing disease severity.
08/23/2024
Long-term Anti-VEGF Less Effective on MNV Lesion Area in those with DR
After 12 months of treatment, the diabetic group showed a smaller reduction than those without the disease, suggesting DR may be a potential treatment modifier in those with comorbid nAMD.
08/20/2024
Upcoming Events
October 8, 2024
Redefine Possibilities For Your Patients and Your Practice
Location: Virtual
Presenters: Mark Schaeffer, OD
Webinar: 8:00pm ET
Sponsored by Bausch + Lomb
October 9, 2024
Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition
Location: Virtual
Presenters: Amr Kouchouk, MD, and Casey Claypool, OD
Webinar: 9:00pm ET
Sponsored by Bausch + Lomb
October 29, 2024
Redefine Possibilities For Your Patients and Your Practice
Location: Virtual
Presenters: Erick Henderson, OD
Webinar: 9:00pm ET
Sponsored by Bausch + Lomb
